Cambrex buying Pharmacore in $25M deal


In the second expansion announced this month, generic API maker Cambrex has a deal to buy a clinical supply manufacturer.

East Rutherford, NJ-based Cambrex ($CBM) will pay about $25 million for Pharmacore, which has a 35,000 square-foot facility in High Point, NC, and take on its 60 full-time employees. The facility, which can make batch sizes from milligrams to 100 kilos, is also licenced with the Drug Enforcement Administration to produce schedule II through schedule V controlled substances, Cambrex said.  

With Pharmacore generating $15 million to $17 million a year in revenues, Cambrex said it expects the addition to be accretive to its earnings next year.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

“The acquisition will provide the capability and expertise to efficiently develop early clinical phase products and new technologies,” Cambrex CEO.Steven Klosk said in a statement.

Earlier this month, Cambrex said it would invest about $9 million to expand its large-scale manufacturing capacity at its Karlskoga facility in Sweden. That project includes adding  new multi-purpose reactors and upgrading of the control room within an existing plant on site. The new facilities are expected to ready to go in Q4 of this year.

Last year, Cambrex announced it would spend about $50 million to add reactors and warehouse space at a facility in Charles City, IA and add about 30 jobs.

Related Article: 
Cambrex ponies up $50M for another expansion of its Iowa API plant


Suggested Articles

Indoco Remedies is not just getting the once over by the FDA but the twice-over as inspectors work through its plants and citations rain down. 

Drugmakers have speculated about delivering temperature-sensitive vaccines and drugs using drones. Now, Merck & Co. is testing the method. 

Nexus Pharmaceuticals has moved forward the first phase of a 10-year, $250 million project to build out its sterile drug production operations.